TEL AVIV, Israel, May 17, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and ...

New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering ...

Novo Nordisk’s Ibrahim Kamstrup-Akkaoui outlines how the Danish GLP-1 giant is embedding AI into its clinical foundation.

Developed in collaboration with Korea's top clinical and hospital network, the integrated platform combines globally ...

AMPLIFY-7P did not meet the pre-specified primary endpoint of disease-free survival (“DFS”) in the intent-to-treat population.Randomization ...

Former ImCheck Therapeutics clinical leader joins HEPHAISTOS-Pharma as the company prepares to advance its lead innate immunotherapy candidate into first-in-human studies Paris, France - May 19, 2026 ...

When healthtech and medtech companies fail, it's often not because their innovation lacks merit. It's due to foundational ...

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the appointment of two technology and clinical development leaders to senior roles to significantly strengthen the ...

Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for ...

Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight The glioblastoma clinical trial analysis report delivers important insights into ...

Clearance enables Phase 2 evaluation of NEO212, the Company’s oral perillyl alcohol-temozolomide conjugate, in the United ...

QuantHealth, the leader in AI-powered clinical trial simulation, today announced the appointment of four executives from the world’s top pharmaceutical and AI organizations to its executive team. The ...